Carr A, Samaras K, Thorisdottir A.
et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor
associated lipodystrophy, hyperlipidemia, and diabetes mellitus. Lancet.1999;353:2093-2099.
Dong KL, Bausserman LL, Flynn MM.
et al. Changes in body habitus and serum lipid abnormalities in HIV-positive
women on highly active antiretroviral therapy. J Acquir Immune Defic Syndr.1999;21:107-113.
Gervasoni C, Ridolfo AL, Trifiro G.
et al. Redistribution of body fat in HIV-infected women undergoing combined
antiretroviral treatment. AIDS.1999;13:465-471.
Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. "Buffalo hump" in men with HIV-I infection. Lancet.1998;351:867-870.
Miller KD, Jones E, Yanovski JA.
et al. Visceral abdominal fat accumulation associated with use of indinavir. Lancet.1998;351:871-875.
Roth VR, Kravcik S, Angel JB. Development of cervical fat pads following therapy with human immunodeficiency
virus type 1 protease inhibitors. Clin Infect Dis.1998;27:65-67.
Carr A, Samaras K, Burton S.
et al. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin
resistance in patients receiving protease inhibitor therapy. AIDS.1998;12:F51-F58.
Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease-inhibitor-associated peripheral lipodystrophy,
hyperlipidemia and insulin resistance. Lancet.1998;351:1881-1883.
Hadigan C, Miller K, Corcoran C.
et al. Fasting hyperinsulinemia and changes in regional body composition in
HIV-infected women. J Clin Endocrinol Metab.1999;84:1932-1937.
Hadigan C, Corcoran C, Stanley T.
et al. Fasting hyperinsulinemia in HIV-infected men. J Clin Endocrinol Metab.2000;85:35-41.
Vigouroux C, Gharakhanian S, Salhi Y.
et al. Diabetes, insulin resistance and dyslipidemia in lipodystrophic HIV-infected
patient on highly active antiretroviral therapy (HAART). Diabetes Metab.1999;25:225-232.
Walli RK, Herfort O, Michl GM.
et al. Treatment with protease inhibitors associated with peripheral insulin
resistance and impaired oral glucose tolerance in HIV-1 infected patients. AIDS.1998;12:F167-F173.
Pyorala K, Savolainen E, Kaukola S, Haapakoski J. Plasma insulin as coronary heart disease risk factor. Acta Med Scand Suppl.1985;701:38-52.
Pyorala M, Miettinen H, Laakso M, Pyorala K. Hyperinsulinemia predicts coronary heart disease in healthy middle
aged men. Circulation.1998;98:398-404.
Despres JP, Lamarche B, Mauriege P.
et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med.1996;334:952-957.
WHO Expert Committee on Diabetes Mellitus. WHO Expert Committee on Diabetes Mellitus: second report. World Health Organ Tech Rep Ser.1980;646:1-80.
Borkan GA, Gerzof SG, Robbins AH, Silbert CK, Silbert JE. Assessment of abdominal fat content by computed tomography. Am J Clin Nutr.1982;36:172-177.
Walli RK, Michl GM, Bogner JR, Goebel FD. Effects of the PPAR-activator troglitazone on protease inhibitor associated
peripheral insulin resistance. Paper presented at: 6th Conference on Retroviruses and Opportunistic
Infections; January 31–February 4, 1999; Chicago, Ill.
Saint-Marc T, Touraine JL. Effects of metformin on insulin resistance and central adiposity in
patients receiving effective protease inhibitor therapy. AIDS.1999;13:1000-1002.
Defronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med.1999;131:281-303.
Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse transcriptase
inhibitors is a key factor in the pathogenesis of antiretroviral therapy-related
Velazquez EM, Mendoza SG, Wang P, Glueck CJ. Metformin therapy is associated with a decrease in plasma plasminogen
activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in
patients with the polycystic ovary syndrome. Metabolism.1997;46:454-457.
Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW. Body mass index and mortality in a prospective cohort of US adults. N Engl J Med.1999;341:1097-1105.
Stokes JL, Kannel WB, Wolf PA.
et al. Blood pressure as a risk factor for cardiovascular disease: the Framingham
Anderson RL, Hamman RF, Savage PJ.
et al. Exploration of simple insulin sensitivity measures derived from frequently
sampled intravenous glucose tolerance (FSIGT) tests. Am J Epidemiol.1995;142:724-732.
Peiris AN, Sothman MS, Hoffman RG.
et al. Adiposity, fat distribution and cardiovascular risk. Ann Intern Med.1989;110:867-872.